Navigation Links
Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
Date:10/23/2007

ent options available to them. We believe PROVENGE has the potential to offer both oncologists and urologists a well tolerated treatment option for their patients that has the ability to extend survival."

The IMPACT study enrolled more than 500 patients at 70 centers in the United States and Canada. Patients with metastatic androgen-independent prostate cancer were eligible for the study. The primary endpoint of the study is overall survival (an event-driven analysis), and time to objective disease progression is a secondary endpoint. The company currently expects an interim analysis for overall survival to be performed in the second half of 2008.

"This study provides the medical community an important opportunity to better define the efficacy and safety profile of PROVENGE in men with metastatic androgen-independent prostate cancer," said Philip Kantoff, M.D., a principal investigator of IMPACT and chief clinical research officer and chief of the Division of Solid Tumor Oncology at the Dana-Farber Cancer Institute. "Considering the limited treatment options available to these critically ill patients, there is a real need for new, safe and effective treatments, particularly those providing a survival benefit."

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 218,890 new cases expected to be diagnosed in 2007, and more than 27,000 men expected to die this year from the disease. Currently, there are limited treatment options for men with advanced, metastatic prostate cancer.

Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to re-engage the patient's own immune system with the goal of turning it "back on" to elicit a sp
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Presentation of Data at American Urological Association Annual Meeting
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
7. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
8. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
9. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
10. Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
11. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global ... to develop, manufacture and sell enzymes and other proteins ... industries, announced today that it will report its financial ... after market close on Thursday, August 14, 2014 and ... p.m. Eastern Time to discuss those results. ...
(Date:7/31/2014)... , Indien, August 1, 2014 /PRNewswire/ ... und BioQuiddity Inc. gaben heute bekannt, vor ... regionalen Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen Eingriffen ... das Gebiet der Europäischen Union und weiterer ... CE-Kennzeichnung versehene und mit Ropivacain gefüllte OneDose ...
(Date:7/31/2014)... STAAR Surgical Company (NASDAQ: STAA ... lenses and delivery systems for the eye today reported ... of $20.0 million, a 10% increase over $18.2 million ... constant currency basis, revenues grew 11% during the second ... 2013.  The effect of foreign currency exchange reduced sales ...
Breaking Medicine Technology:Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... , BOSTON, Nov. 17 ... and information management solutions, today announced that it will showcase ... (IDNs) at the 2009 Radiological Society of North America (RSNA) ... IL. AMICAS will be in the North Hall in booth ...
... HistoRx today announced that the Company,s proprietary AQUA technology, ... was noted in a recent National Comprehensive Cancer ... testing in breast cancer as one of the "... promising ... PgR in breast cancer tissue." Experts from the country,s ...
Cached Medicine Technology:AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 2AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 3AQUA(R) Technology Recognized as 'Promising New Strategy' for Hormone Receptor Testing in Breast Cancer by NCCN Task Force 2
(Date:8/1/2014)... 01, 2014 Cannabis use among young people ... 14 to 17 having used marijuana at least once and ... slogan “Say ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers ... to youth this summer with factual information about drugs, to ... months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” ...
(Date:8/1/2014)... Washington University School of Medicine in St. Louis helps ... and frequently are more harmful than similar tumors in ... tumors, are diagnosed twice as often in males, who ... survive as long. , The researchers found that retinoblastoma ... is significantly less active in male brain cells than ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, ... manufacturing jobs may have significantly less endurance than those who weigh ... people -- half were obese, half were of normal weight -- ... 60 percent longer. Obesity also was associated with less strength, ... older -- 50 to 65 years of age -- neither improved ...
(Date:8/1/2014)... News) -- Almost 140 people die every year ... United States. But there are several simple ... injury prevention coordinator at Cincinnati Children,s Hospital Medical ... medical center news release. "As families begin ... important for parents and children to go over ...
(Date:8/1/2014)... 2014 Summer is here, and with it ... the summer, and they can be a pain for dogs. ... help all their customers get rid of ticks and prevent ... eggs in the summer, which is why they are so ... grass and woodland areas and carry a number of diseases, ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Study reveals one reason brain tumors are more common in men 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2
... each year , , THURSDAY, Jan. 15 (HealthDay News) -- A ... is 300 times more likely to die during pregnancy or ... annual report released Thursday shows. , The State of ... in developing nations have a 14-fold higher chance of dying ...
... Online Care service available to all Hawaii residents.HONOLULU, Jan. 15 ... launch of its new Online Care service that connects patients ... Care is now available to everyone in Hawaii and may ... not have to be an HMSA member to use the ...
... a leading middle market investment bank recently released ... Information and Technology M&A Trends Report . ... 2008 and compares it with activity during the ... and healthcare information and technology markets.(Photo: ...
... Nonin Medical, Inc., a leading,innovator of physiological ... SIG Best of CES 2009 award for the ... world,s first wireless fingertip oximeter,the innovative device combines ... -- enabling individuals to accurately,monitor vital signs. , ...
... sell homes, seniors increasingly turning to home care vs. ... real estate crisis has affected all aspects of life, ... seniors unable to sell their homes, moving to an ... this reason, the option of aging-in-place with retrofits is ...
... because they may lead to blood clots, study says ... birth control pills don,t seem to increase the risk of ... study says. , But more research on the newer ... This is especially true because more women over age 35 ...
Cached Medicine News:Health News:Mothers, Newborns at High Risk in Developing World 2Health News:First in the Nation, HMSA's Online Care Goes Live 2Health News:First in the Nation, HMSA's Online Care Goes Live 3Health News:First in the Nation, HMSA's Online Care Goes Live 4Health News:Berkery Noyes Report Shows Pharma and Healthcare Information and Technology M&A Remained Strong in 2008 2Health News:Nonin Medical's Onyx(R) II, Model 9560 Receives Bluetooth SIG's Best of CES 2009 Award 2Health News:Housing Crisis Affects Seniors Needing Care 2Health News:Housing Crisis Affects Seniors Needing Care 3Health News:Newer Contraceptives Don't Increase Heart Risk 2Health News:Newer Contraceptives Don't Increase Heart Risk 3
... Proven tension-free sling technology ... porcine acellular collagen matrix sling, ... tissue-to-tissue contact between sling and ... urethral or vaginal abrasion or ...
... Delivers the advanced performance ... exceptional strength, versatility, and durability ... implant that augments the effectiveness ... pelvic floor reconstruction. Comprised of ...
... system is a state-of-the-art, comprehensive cardiac ... programs, modalities, and parameters are highly ... multiple applications including cardiac and pulmonary ... clinics. Its open architecture delivers flexibility ...
NephroMax High Pressure Nephrostomy Balloon Catheter allows one-step, atraumatic dilatation of the nephrostomy tract....
Medicine Products: